+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Duchenne Muscular Dystrophy (DMD) Therapeutics Market By Type (Small Molecules and Biologics): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 - 2025

  • ID: 5143503
  • Report
  • February 2020
  • Region: Global
  • 110 pages
  • Zion Market Research
The report covers forecast and analysis for the Duchenne Muscular Dystrophy (DMD) therapeutics market on a global and regional level. The study provides historic data from 2016 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the Duchenne Muscular Dystrophy (DMD) therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Duchenne Muscular Dystrophy (DMD) therapeutics market on a global as well as regional level.

According to the report, global demand for Duchenne Muscular Dystrophy (DMD) therapeutics market was valued at approximately USD 2.36 Billion in 2018, and is expected to generate revenue of around USD 20.56 Billion by end of 2025, growing at a CAGR of around 36.3% between 2019 and 2025.

In order to give the users of this report a comprehensive view on the Duchenne Muscular Dystrophy (DMD) therapeutics market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein type segment is benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the Duchenne Muscular Dystrophy (DMD) therapeutics market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the Duchenne Muscular Dystrophy (DMD) therapeutics market on global and regional basis.

Duchenne muscular dystrophy is a harsh kind of muscular dystrophy. The indication of muscle weakness typically begins at the age of four in boys and deteriorates rapidly. Most of the affected people are incapable of walking by the age of 12. The affected muscles tend to look bigger because of augmented fat content. Constant research efforts in comprehending the etiology of Duchenne muscular dystrophy gave way to the recognition of the dystrophin gene that is accountable for coding patients.

Factors such as growing funding for research and development activities and technological advancements in diagnostic techniques will act as major driving factors in the growth of global Duchenne Muscular Dystrophy (DMD) therapeutics market. Efforts taken by governments and non-government organizations to create awareness will act as an opportunity for the market players in the Duchenne Muscular Dystrophy (DMD) therapeutics market. Nonetheless, lack of awareness and dearth of skilled researchers will restrict the growth of global Duchenne Muscular Dystrophy (DMD) therapeutics market.

The global Duchenne Muscular Dystrophy (DMD) therapeutics market has been split into type and region. Based on type, Duchenne Muscular Dystrophy (DMD) therapeutics market has been segmented into small molecules and biologics. The biologics segment accounted for the highest market share in 2018 due to ongoing research on biologics and anticipated launch of biologics currently in late phases of clinical trials.

North America will be the leading region during the forecast period. High investment in research and development of Duchenne Muscular Dystrophy (DMD) therapeutics and presence of major manufacturers will boost the market growth in this region. Europe is expected to be the second major market. The key reasons are efforts taken by health agencies and advantageous reimbursement scenario. Asia Pacific will grow at rapid rate over the forecast time-frame due to increasing investment in research and development to develop new products. The market in Latin America will grow at a substantial rate during the estimate period. The Africa and Middle Eastern region is expected to exhibit definite progression in the anticipated time-frame.

The report also includes detailed profiles of key players such as PTC Therapeutics Inc., F. Hoffmann-La Roche Ltd., Santhera Pharmaceuticals, Wave Life Sciences Ltd., and Sarepta Therapeutics Inc. among others.

This report segments the Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market as follows:

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: By Type
  • Small Molecules
  • Biologics
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: By Region
  • North America
  • The U.S.
  • Canada
  • Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa
Note: Product cover images may vary from those shown
  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
    • 2.2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Snapshot
  • Chapter 3. Duchenne Muscular Dystrophy (DMD) Therapeutics Market – Industry Analysis
    • 3.1. Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Growing funding for research and development activities
      • 3.2.2. Technulogical advancements in diagnostic techniques
    • 3.3. Restraints
      • 3.3.1. Lack of awareness
      • 3.3.2. Dearth of skilled researchers
    • 3.4. Opportunities
      • 3.4.1. Efforts taken by governments and non-government organizations to create awareness
    • 3.5. Porter’s Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Type
      • 3.6.2. Market attractiveness analysis by Region
  • Chapter 4. Duchenne Muscular Dystrophy (DMD) Therapeutics Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market –Type Analysis
    • 5.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market overview: By Type
      • 5.1.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market share, By Type,2018 and 2025
    • 5.2. Small Mulecules
      • 5.2.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Small Mulecules, 2016–2025 (USD Billion)
    • 5.3. Biulogics
      • 5.3.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Biulogics, 2016–2025 (USD Billion)
  • Chapter 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market - Regional Analysis
    • 6.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market overview: by Region
      • 6.1.1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market share, by Region, 2018 and 2025
    • 6.2. North America
      • 6.2.1. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
      • 6.2.2. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
      • 6.2.3. U.S.
        • 6.2.3.1. U.S. Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
      • 6.2.4. Rest of North America
        • 6.2.4.1. Rest of North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
    • 6.3. Europe
      • 6.3.1. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
      • 6.3.2. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
      • 6.3.3. UK
        • 6.3.3.1. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
      • 6.3.4. France
        • 6.3.4.1. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
      • 6.3.5. Germany
        • 6.3.5.1. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
      • 6.3.6. Rest of Europe
        • 6.3.6.1. Rest of Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
      • 6.4.2. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
      • 6.4.3. China
        • 6.4.3.1. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
      • 6.4.4. Japan
        • 6.4.4.1. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
      • 6.4.5. India
        • 6.4.5.1. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
      • 6.4.6. Rest of Asia Pacific
        • 6.4.6.1. Rest of Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
    • 6.5. Latin America
      • 6.5.1. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
      • 6.5.2. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
      • 6.5.3. Brazil
        • 6.5.3.1. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
      • 6.5.4. Rest of Latin America
        • 6.5.4.1. Rest of Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
    • 6.6. The Middle East and Africa
      • 6.6.1. The Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market, 2016–2025 (USD Billion)
      • 6.6.2. The Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market revenue, By Type,2016–2025 (USD Billion)
  • Chapter 7. Company Profiles
    • 7.1. PTC Therapeutics Inc.
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Type Portfolio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. F. Hoffmann-La Roche Ltd.
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Type Portfolio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Santhera Pharmaceuticals
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Type Portfolio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Wave Life Sciences Ltd.
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Type Portfolio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. Wave Life Sciences Ltd.
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Type Portfolio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
Note: Product cover images may vary from those shown
Adroll
adroll